GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Total Stockholders Equity

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Total Stockholders Equity : NT$618.04 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Total Stockholders Equity?

Great Novel Therapeutics Biotech & Medicals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$618.04 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Great Novel Therapeutics Biotech & Medicals's Book Value per Share for the quarter that ended in Dec. 2023 was NT$15.50. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Great Novel Therapeutics Biotech & Medicals's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.02.


Great Novel Therapeutics Biotech & Medicals Total Stockholders Equity Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Total Stockholders Equity Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial 67.01 120.55 208.36 360.80 618.04

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 208.36 182.17 360.80 641.02 618.04

Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Great Novel Therapeutics Biotech & Medicals's Book Value per Share for the quarter that ended in Dec. 2023 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Great Novel Therapeutics Biotech & Medicals's Debt-to-Equity for the quarter that ended in Dec. 2023 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Great Novel Therapeutics Biotech & Medicals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines